These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 33846715)

  • 1. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study.
    Skiba MA; Bell RJ; Herbert D; Garcia AM; Islam RM; Davis SR
    Hum Reprod; 2021 May; 36(6):1611-1620. PubMed ID: 33846715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
    Bell RJ; Islam RM; Skiba MA; Herbert D; Martinez Garcia A; Davis SR
    Hum Reprod; 2021 Dec; 37(1):109-118. PubMed ID: 34741176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource.
    Azziz R; Kintziger K; Li R; Laven J; Morin-Papunen L; Merkin SS; Teede H; Yildiz BO
    Hum Reprod; 2019 Nov; 34(11):2254-2265. PubMed ID: 31751476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
    Lie Fong S; Laven JSE; Duhamel A; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
    Bozdag G; Mumusoglu S; Zengin D; Karabulut E; Yildiz BO
    Hum Reprod; 2016 Dec; 31(12):2841-2855. PubMed ID: 27664216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
    Teede HJ; Tay CT; Laven JJE; Dokras A; Moran LJ; Piltonen TT; Costello MF; Boivin J; Redman LM; Boyle JA; Norman RJ; Mousa A; Joham AE
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2447-2469. PubMed ID: 37580314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.
    Lauritsen MP; Bentzen JG; Pinborg A; Loft A; Forman JL; Thuesen LL; Cohen A; Hougaard DM; Nyboe Andersen A
    Hum Reprod; 2014 Apr; 29(4):791-801. PubMed ID: 24435776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding variation in prevalence estimates of polycystic ovary syndrome: a systematic review and meta-analysis.
    Skiba MA; Islam RM; Bell RJ; Davis SR
    Hum Reprod Update; 2018 Nov; 24(6):694-709. PubMed ID: 30059968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.
    Teede HJ; Tay CT; Laven J; Dokras A; Moran LJ; Piltonen TT; Costello MF; Boivin J; M Redman L; A Boyle J; Norman RJ; Mousa A; Joham AE;
    Fertil Steril; 2023 Oct; 120(4):767-793. PubMed ID: 37589624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†.
    Teede HJ; Tay CT; Laven J; Dokras A; Moran LJ; Piltonen TT; Costello MF; Boivin J; Redman LM; Boyle JA; Norman RJ; Mousa A; Joham AE;
    Hum Reprod; 2023 Sep; 38(9):1655-1679. PubMed ID: 37580037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
    Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
    Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In utero exposure to maternal stressful life events and risk of polycystic ovary syndrome in the offspring: The Raine Study.
    Koch T; Doherty DA; Dickinson JE; Juul A; Hart R; Bräuner EV; Hickey M
    Psychoneuroendocrinology; 2021 Mar; 125():105104. PubMed ID: 33352473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.
    Dewailly D; Alebić MŠ; Duhamel A; Stojanović N
    Hum Reprod; 2014 Nov; 29(11):2536-43. PubMed ID: 25267785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
    Eilertsen TB; Vanky E; Carlsen SM
    Hum Reprod; 2012 Aug; 27(8):2494-502. PubMed ID: 22693172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population.
    Bozdag G; Mumusoglu S; Coskun ZY; Yarali H; Yildiz BO
    Reprod Biomed Online; 2019 Sep; 39(3):522-529. PubMed ID: 31182353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis delayed: health profile differences between women with undiagnosed polycystic ovary syndrome and those with a clinical diagnosis by age 35 years.
    Fernandez RC; Moore VM; Rumbold AR; Whitrow MJ; Avery JC; Davies MJ
    Hum Reprod; 2021 Jul; 36(8):2275-2284. PubMed ID: 33963388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the newly recommended antral follicle count cutoff for polycystic ovary in adult women with polycystic ovary syndrome.
    Kim JJ; Hwang KR; Chae SJ; Yoon SH; Choi YM
    Hum Reprod; 2020 Mar; 35(3):652-659. PubMed ID: 32211797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.